Organization
German Center for Lung Research (DZL)
7 abstracts
Abstract
Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.Org: Hospital Universitario 12 de Octubre, Madrid, Spain, Hospital Universitari i Politécnic La Fe de Valencia, Valencia, Spain, Henry Dunant Hospital Center, Athens, Greece, Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain, Asklepios Lung Clinic, German Center for Lung Research (DZL), Munich-Gauting, Germany,
Abstract
Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with PD-L1 ≥ 50%: Cohort A of EVOKE-02.Org: Northwestern University Feinberg School of Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Regional and Virgen de la Victoria University Hospitals, IBIMA, Hospital Clínic de Barcelona, IDIBAPS,
Abstract
Early detection of lung cancer using small RNAs.Org: Hummingbird Diagnostics, Klinikverbund Allgäu, Klinikum Konstanz, Translational Lung Research Center Heidelberg, University Hospital Essen,
Abstract
The impact of PD-L1 expression and co-mutations on outcome of KRAS-driven non-small-cell lung cancer.Org: Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, Thoraxklinik, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), University Hospital Heidelberg,
Abstract
Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION study.Org: Memorial Sloan-Kettering Cancer Center, Knapp Center for Biomedical Discovery, The University of Chicago Medicine Center for Advanced Care at Orland Park, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Thoraxklinik,
Abstract
Clinical evidence and benefit of special FDA designations in anti-cancer drugs.Org: DKFZ-Hector Cancer Institute and Department of Personalized Oncology, University Medical Center Mannheim, Division of Personalized Medical Oncology, German Cancer Research Center (DKFZ), German Center for Lung Research (DZL),
Abstract
Association of SARS-CoV-2 vaccinations and personal protective measures with seroconversion and risk of infection in a large real-world cohort of patients with cancer.Org: DKFZ-Hector Cancer Institute and Department of Personalized Oncology, University Medical Center Mannheim, Division of Personalized Medical Oncology, German Cancer Research Center (DKFZ), German Center for Lung Research (DZL),